Biomodulatory Treatment Regimen, MEPED, Rescues Relapsed and Refractory Classic Hodgkin’s Disease

Biomodulatory Treatment Regimen, MEPED, Rescues Relapsed and Refractory Classic Hodgkin’s Disease

Introduction: Current combined intensive chemotherapy and radiation regimens yield excellent survival rates in advanced classic Hodgkin’s lymphoma (cHL). However, acute toxicity in elderly, comorbid patients can be challenging and long-term survival in refractory patients remains poor.Patients and M...

Full description

Bibliographic Details
Main Authors: Florian Lüke, Dennis C. Harrer, Karin Menhart, Daniel Wolff, Ernst Holler, Dirk Hellwig, Wolfgang Herr, Matthias Grube, Martin Vogelhuber, Albrecht Reichle, Daniel Heudobler
Format: Article
Language:English
Published: Frontiers Media S.A. 2021-06-01
Series:Frontiers in Pharmacology
Subjects:
metronomic low dose chemotherapy
everolimus
piogliatazone
etoricoxib
anakoinosis
r/r Hodkin's disease
Online Access:https://www.frontiersin.org/articles/10.3389/fphar.2021.599561/full

Internet

https://www.frontiersin.org/articles/10.3389/fphar.2021.599561/full

Similar Items